论文部分内容阅读
目的观察他克莫司胶囊联合醋酸泼尼松龙片治疗系统性红斑狼疮的临床疗效及安全性。方法将54例系统性红斑狼疮患者随机分为对照组27例和试验组27例。对照组予以醋酸泼尼松龙每次40 mg,qd,口服;试验组在对照组治疗的基础上,予以他克莫司胶囊每次1 mg,bid,口服。2组患者均治疗1个月。比较2组患者的临床疗效、血清白细胞介素-4(IL-4)、单核细胞趋化蛋白-4(MCP-4)水平、白细胞、血小板、红细胞沉降率,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为92.59%(25/27例)和70.37%(19/27例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的IL-4分别为(135.67±16.88),(165.47±23.22)ng·L~(-1);MCP-4分别为(3.17±0.46),(4.98±0.71)ng·L~(-1);白细胞分别为(4.83±0.58)×10~9,(3.67±0.46)×10~9/L;血小板分别为(1 5 3.2 2±1 8.8 5)×1 0~9,(113.22±16.26)×10~9/L;红细胞沉降率分别为(15.26±3.14),(23.65±3.58)mm·h~(-1),差异均有统计学意义(P<0.05)。2组患者的药物不良反应以白细胞下降、消化道不适、感染为主,试验组和对照组的药物不良反应发生率分别为18.52%和14.81%,差异无统计学意义(P>0.05)。结论他克莫司胶囊联合醋酸泼尼松龙片治疗系统性红斑狼疮的临床疗效显著,其能明显地降低患者的IL-4及MCP-4水平,且不增加药物不良反应的发生率。
Objective To observe the clinical efficacy and safety of tacrolimus combined with Prednisolone Acetate in the treatment of systemic lupus erythematosus. Methods 54 patients with systemic lupus erythematosus were randomly divided into control group (27 cases) and experimental group (27 cases). The control group was treated with prednisolone acetate 40 mg qd orally every day. On the basis of the treatment of the control group, the experimental group was given 1 mg bid of tacrolimus once daily for oral administration. Two groups of patients were treated for 1 month. The clinical efficacy, levels of serum interleukin-4 (IL-4), monocyte chemoattractant protein-4 (MCP-4), white blood cells, platelets, erythrocyte sedimentation rate and adverse drug reactions were compared between the two groups . Results After treatment, the total effective rates in the experimental group and the control group were 92.59% (25/27 cases) and 70.37% (19/27 cases), respectively, with statistical significance (P <0.05). After treatment, the levels of IL-4 in the experimental group and the control group were (135.67 ± 16.88) and (165.47 ± 23.22) ng · L -1, respectively. The MCP-4 levels were 3.17 ± 0.46 and 4.98 ± 0.71, ng · L -1; white blood cells were (4.83 ± 0.58) × 10 ~ 9, (3.67 ± 0.46) × 10 ~ 9 / L respectively; platelets were (1 5 3.2 2 ± 1 8.8 5) × 10 ~ (9), (113.22 ± 16.26) × 10 ~ 9 / L respectively, and the erythrocyte sedimentation rates were (15.26 ± 3.14) and (23.65 ± 3.58) mm · h ~ ). Adverse reactions to the two groups of patients with leukopenia, gastrointestinal discomfort, infection, the experimental group and control group, the incidence of adverse drug reactions were 18.52% and 14.81%, respectively, with no significant difference (P> 0.05). Conclusion The clinical efficacy of tacrolimus combined with prednisone acetate tablets in the treatment of systemic lupus erythematosus is significant. It can significantly reduce the level of IL-4 and MCP-4 in patients without increasing the incidence of adverse drug reactions.